IP Library Granted Patent US 11,229,607
Granted Patent B2
US 11,229,607 · App. 15/321,458 · Granted Jan 25, 2022

Hydrogel compositions comprising encapsulated cells and methods of use thereof

Inventors: Jae-Won Shin (Cambridge, MA); Angelo S. Mao (Cambridge, MA); Stefanie Utech (Cambridge, MA); David A. Weitz (Cambridge, MA); David J. Mooney (Sudbury, MA); Oktay Uzun (Boston, MA)
Assignee: President and Fellows of Harvard College
A61K9/4816A61K9/0019A61K9/5036A61K9/5052A61K35/12A61K35/28C12N11/04C12N11/10A61K2035/124
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,229,607
App. No.
15/321,458
Granted
Jan 25, 2022
Kind
B2
Abstract

The present invention provides injectable compositions comprising cells encapsulated in hydrogel capsules and methods of preparing these compositions. The present invention also provides methods for using these compositions to promote hematopoiesis and to treat or prevent cardiovascular and immunological disorders in a subject.

Claims (29)

1. A composition comprising a plurality of hydrogel capsules, wherein at least 90% of the hydrogel capsules in the composition comprise a cell and a layer consisting of hydrogel encapsulating the cell;

wherein at least 70% of the hydrogel capsules encapsulate a single cell;

wherein the layer consisting of hydrogel encapsulating the cell has a thickness of less than 20 microns;

wherein the hydrogel comprises an alginate polymer comprising a plurality of polymer chains cross-linked to each other using Ca 2+ ; and

wherein the diameter of the hydrogel capsules is 50 microns or less.

2. The composition of claim 1 , wherein the cell is a mesenchymal stem cell (MSC) or a progenitor thereof, a hematopoietic stem cell (HSC) or a progenitor thereof, or an endothelial progenitor cell.

3. The composition of claim 1 , wherein the layer consisting of hydrogel encapsulating the cell is characterized by a stiffness of about 0.1 to about 500 kPa.

4. The composition of claim 1 , wherein the composition is an injectable composition.

5. The composition of claim 4 , wherein the composition is an injectable composition for intravenous injection.

6. A composition comprising a plurality of hydrogel capsules, wherein

at least 90% of the hydrogel capsules in the composition comprise a cell and a layer consisting of hydrogel encapsulating the cell;

wherein at least 70% of the hydrogel capsules comprise a single cell;

wherein the layer consisting of hydrogel encapsulating said cell has a thickness of less than 10 microns;

wherein the hydrogel comprises an alginate polymer comprising a plurality of polymer chains cross-linked to each other using Ca 2+ ; and

wherein the diameter of the hydrogel capsules is 50 microns or less.

7. The composition of claim 6 , wherein the cell is a mesenchymal stem cell (MSC) or a progenitor thereof, a hematopoietic stem cell (HSC) or a progenitor thereof, or an endothelial progenitor cell.

8. The composition of claim 6 , wherein the layer consisting of hydrogel encapsulating the cell is characterized by a stiffness of about 0.1 to about 500 kPa.

9. The composition of claim 6 , wherein the composition is an injectable composition.

10. The composition of claim 9 , wherein the composition is an injectable composition for intravenous injection.

11. A method of preparing a composition comprising a plurality of hydrogel capsules, the method comprising:

a) contacting a cell with a moiety capable of adhering to a cell and comprising a cross-linking catalyst, wherein the cross-linking catalyst is Ca 2+ ; and

b) contacting the cell and the moiety with an alginate polymer comprising a plurality of polymer chains;

wherein the cross-linking catalyst catalyzes a reaction that cross-links the plurality of polymer chains, thereby forming a composition comprising a plurality of hydrogel capsules, wherein at least 90% of the hydrogel capsules in the composition comprise a cell and a layer consisting of hydrogel encapsulating the cell;

wherein at least 70% of the hydrogel capsules encapsulate a single cell;

wherein the layer consisting of hydrogel encapsulating the cell has a thickness of less than 20 microns; and

wherein the diameter of the hydrogel capsules is 50 microns or less.

12. The method of claim 11 , wherein the moiety is a nanoparticle.

13. The method of claim 12 , wherein the nanoparticle is a CaCO 3 nanoparticle.

14. The method of claim 11 , wherein the cell is a mesenchymal stem cell (MSC) or a progenitor thereof, a hematopoietic stem cell (HSC) or a progenitor thereof, or an endothelial progenitor cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2017
From: MAO, ANGELO S.; MOONEY, DAVID J.; SHIN, JAE-WON; UTECH, STEFANIE; UZUN, OKTAY; WEITZ, DAVID A.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 041622/0381 →
CONFIRMATORY LICENSE Recorded Jan 10, 2017
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 041311/0239 →
Continuity (3)
Provisional Application 62082993 · Nov 21, 2014
Provisional Application 62019284 · Jun 30, 2014
Related Publication 20170196818A1 · Jul 13, 2017